Reade revalidatie & reumatologie centrum te Amsterdam
- Address
- Admiraal Helfrichstraat 1
Sponsor Overview
Specializations
Rheumatoid arthritis and inflammatory joint disease
The clinical research activity centres on rheumatoid arthritis, with studies focused on patients diagnosed according to established ACR/EULAR criteria. The sponsor’s trial portfolio reflects a strong interest in disease control, symptom burden, and treatment optimisation in chronic inflammatory arthritis.
- Rheumatoid arthritis
- Disease Activity Score in 28 joints (DAS28-ESR)
- Inflammatory arthritis
Research activity includes treatment adjustment strategies aimed at maintaining control of joint inflammation while improving long-term management of RA.
Targeted immunomodulatory therapy
The sponsor is involved in research on advanced immunomodulatory treatment approaches for rheumatoid arthritis, including therapies that act on key inflammatory signalling pathways. This area of interest highlights the role of modern immune-directed treatment in controlling persistent disease activity.
- Janus kinase inhibitors
- Tocilizumab
- Biologic therapy
The trial portfolio includes questions around treatment maintenance and dose optimisation in patients receiving biologic or targeted therapy.
Cardiac involvement in rheumatoid arthritis
One research focus examines the relationship between rheumatoid arthritis treatment and cardiac function, with attention to myocardial inflammation and coronary plaque morphology. This indicates interest in the cardiovascular aspects of inflammatory disease.
- Cardiac function
- Myocardial inflammation
- Coronary plaque morphology
The studies also address patients without a prior history of cardiovascular disease, supporting investigation of early heart-related involvement in RA.
Treatment optimisation and monitoring
The sponsor’s research includes evaluation of treatment adjustment based on serum trough concentrations and clinical response, with the aim of refining ongoing care in rheumatoid arthritis. This supports interest in personalised management of chronic inflammatory disease.
- Therapeutic drug monitoring
- Dose interval adjustment
- Clinical response assessment
These studies are aligned with practical questions in long-term RA management, particularly where sustained disease control and treatment burden are both relevant.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Concentration-Guided Tocilizumab Dose Reduction Versus Standard Dosing in Rheumatoid Arthritis: A Randomized, International, Multicenter, Non-Inferiority Trial |  The Netherlands | Not Yet Recruiting |
| Evaluation of Filgotinib on Cardiac Function, Myocardial Inflammation, and Coronary Plaque Morphology in Rheumatoid Arthritis Patients Without Cardiovascular History | The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 7 sites across their trial portfolio.
Therapeutic Focus
- 1.Immune System Diseases2 trials322 other sponsors
- 2.Cardiovascular Diseases1 trial359 other sponsors
Partnered Research Centres
7 centres- Address
- De Boelelaan 1117, 1081 HV Amsterdam
- Address
- Dr. Molewaterplein 40, 3015 GD Rotterdam
- Address
- Maasstadweg 21, 3079 DZ Rotterdam
- Address
- Wilhelminalaan 12, 1815 JD Alkmaar
- Address
- Admiraal Helfrichstraat 1, 1056 AA Amsterdam
- Address
- Hengstdal 3, 6574 NA Ubbergen
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Reade revalidatie & reumatologie centrum te Amsterdam.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.